#METABOLOMICS WORKBENCH borjalanzon_20241216_091130 DATATRACK_ID:5455 STUDY_ID:ST003738 ANALYSIS_ID:AN006136 PROJECT_ID:PR002324
VERSION             	1
CREATED_ON             	February 18, 2025, 7:19 am
#PROJECT
PR:PROJECT_TITLE                 	Impact of Trans-Fatty acids on renal health in mice with partial Tgfβ3
PR:PROJECT_TITLE                 	deletion: a Metabolomic and Lipidomic analysis
PR:PROJECT_TYPE                  	Multiplatform non-targeted metabolomics
PR:PROJECT_SUMMARY               	Trans-fatty acids, prevalent in Western diets, contribute to the onset and
PR:PROJECT_SUMMARY               	progression of renal damage. This study investigates the effects of trans-fat
PR:PROJECT_SUMMARY               	consumption on kidney health using a comprehensive approach encompassing
PR:PROJECT_SUMMARY               	metabolomics, lipidomics, molecular, and cellular analyses. We analyzed both
PR:PROJECT_SUMMARY               	wild-type mice and mice with partial transforming growth factor beta 3 (Tgfβ3)
PR:PROJECT_SUMMARY               	deletion, a model for pre-existing renal damage. In control animals, the
PR:PROJECT_SUMMARY               	trans-fat diet induced significant dysregulation in renal lipid metabolism. Omic
PR:PROJECT_SUMMARY               	analyses revealed a reduction in triglycerides and an increase in plasmalogens,
PR:PROJECT_SUMMARY               	which are associated with cellular protection and signaling. Furthermore,
PR:PROJECT_SUMMARY               	upregulation of Tricarboxylic acid cycle (TCA) metabolites, malic and fumaric
PR:PROJECT_SUMMARY               	acids, indicated mitochondrial dysfunction. In mice with partial Tgfβ3
PR:PROJECT_SUMMARY               	deletion, trans-fat consumption exacerbated renal fibrosis, and further depleted
PR:PROJECT_SUMMARY               	triglycerides and plasmalogens. Despite similar lipid profiles in both groups,
PR:PROJECT_SUMMARY               	Tgfβ3-deleted mice exhibited larger lipid droplets and worsened renal damage,
PR:PROJECT_SUMMARY               	including a notable reduction in taurine levels. This study underscores the
PR:PROJECT_SUMMARY               	value of detailed metabolic profiling to uncover mechanisms driving renal
PR:PROJECT_SUMMARY               	dysfunction linked to harmful dietary habits and genetic mutations.
PR:INSTITUTE                     	Universidad Rey Juan Carlos
PR:DEPARTMENT                    	Basic Sciences of Health
PR:LABORATORY                    	Lipobeta
PR:LAST_NAME                     	Lanzon
PR:FIRST_NAME                    	Borja
PR:ADDRESS                       	Avenida de Atenas S/N
PR:EMAIL                         	borja.lanzon@urjc.es
PR:PHONE                         	663692554
#STUDY
ST:STUDY_TITLE                   	Impact of Trans-Fatty acids on renal health in mice with partial Tgfβ3
ST:STUDY_TITLE                   	deletion: a Metabolomic and Lipidomic analysis
ST:STUDY_TYPE                    	Multiplatform non-targeted metabolomics
ST:STUDY_SUMMARY                 	Trans-fatty acids, prevalent in Western diets, contribute to the onset and
ST:STUDY_SUMMARY                 	progression of renal damage. This study investigates the effects of trans-fat
ST:STUDY_SUMMARY                 	consumption on kidney health using a comprehensive approach encompassing
ST:STUDY_SUMMARY                 	metabolomics, lipidomics, molecular, and cellular analyses. We analyzed both
ST:STUDY_SUMMARY                 	wild-type mice and mice with partial Tgfβ3 deletion, a model for pre-existing
ST:STUDY_SUMMARY                 	renal damage. In control animals, the trans-fat diet induced significant
ST:STUDY_SUMMARY                 	dysregulation in renal lipid metabolism. Omic analyses revealed a reduction in
ST:STUDY_SUMMARY                 	triglycerides and an increase in plasmalogens, which are associated with
ST:STUDY_SUMMARY                 	cellular protection and signaling. Furthermore, upregulation of TCA cycle
ST:STUDY_SUMMARY                 	metabolites, malic and fumaric acids, indicated mitochondrial dysfunction. In
ST:STUDY_SUMMARY                 	mice with partial Tgfβ3 deletion, trans-fat consumption exacerbated renal
ST:STUDY_SUMMARY                 	fibrosis, and further depleted triglycerides and plasmalogens. Despite similar
ST:STUDY_SUMMARY                 	lipid profiles in both groups, Tgfβ3-deleted mice exhibited larger lipid
ST:STUDY_SUMMARY                 	droplets and worsened renal damage, including a notable reduction in taurine
ST:STUDY_SUMMARY                 	levels. This study underscores the value of detailed metabolic profiling to
ST:STUDY_SUMMARY                 	uncover mechanisms driving renal dysfunction linked to harmful dietary habits
ST:STUDY_SUMMARY                 	and genetic mutations.
ST:INSTITUTE                     	Universidad Rey Juan Carlos
ST:DEPARTMENT                    	Basic Sciences of Health
ST:LABORATORY                    	Lipobeta
ST:LAST_NAME                     	Lanzon
ST:FIRST_NAME                    	Borja
ST:ADDRESS                       	Avenida de Atenas S/N
ST:EMAIL                         	borja.lanzon@urjc.es
ST:PHONE                         	663692554
ST:NUM_GROUPS                    	4
ST:TOTAL_SUBJECTS                	28
ST:NUM_MALES                     	28
ST:STUDY_COMMENTS                	Study is composed of 4 groups of mice: wild-type on control diet (WT-CD),
ST:STUDY_COMMENTS                	wild-type on trans diet (WT-HFD), heterozygous TGFBeta 3 on control diet (HZ-CD)
ST:STUDY_COMMENTS                	and heterozygous TGFBeta 3 on trans diet (HZ-HFD)
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
SU:AGE_OR_AGE_RANGE              	16 weeks
SU:WEIGHT_OR_WEIGHT_RANGE        	26 to 32 g
SU:GENDER                        	Male
SU:ANIMAL_FEED                   	Control diet: D12450B, Research Diets. Trans diet: TD.07011, ENVIGO
SU:SPECIES_GROUP                 	4 groups: wild-type animals on control diet (WT-CD), wild-type on trans diet
SU:SPECIES_GROUP                 	(WT-HFD), Heterozygous TGFBeta 3 on control diet (HZ-CD) and Heterozygous
SU:SPECIES_GROUP                 	TGFBeta 3 on trans diet (HZ-HFD)
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	269 HZCD	Sample source:Kidney | Genotype:Heterozygous | Diet:Control	RAW_FILE_NAME(Raw Data File)=HZ-CD 269
SUBJECT_SAMPLE_FACTORS           	-	119 HZCD	Sample source:Kidney | Genotype:Heterozygous | Diet:Control	RAW_FILE_NAME(Raw Data File)=HZ-CD 119
SUBJECT_SAMPLE_FACTORS           	-	267 HZCD	Sample source:Kidney | Genotype:Heterozygous | Diet:Control	RAW_FILE_NAME(Raw Data File)=HZ-CD 267
SUBJECT_SAMPLE_FACTORS           	-	130 HZCD	Sample source:Kidney | Genotype:Heterozygous | Diet:Control	RAW_FILE_NAME(Raw Data File)=HZ-CD 130
SUBJECT_SAMPLE_FACTORS           	-	127 HZCD	Sample source:Kidney | Genotype:Heterozygous | Diet:Control	RAW_FILE_NAME(Raw Data File)=HZ-CD 127
SUBJECT_SAMPLE_FACTORS           	-	98 HZCD	Sample source:Kidney | Genotype:Heterozygous | Diet:Control	RAW_FILE_NAME(Raw Data File)=HZ-CD 98
SUBJECT_SAMPLE_FACTORS           	-	25 HZCD	Sample source:Kidney | Genotype:Heterozygous | Diet:Control	RAW_FILE_NAME(Raw Data File)=HZ-CD 25
SUBJECT_SAMPLE_FACTORS           	-	132 WTCD	Sample source:Kidney | Genotype:Wild-Type | Diet:Control	RAW_FILE_NAME(Raw Data File)=WT-CD 132
SUBJECT_SAMPLE_FACTORS           	-	251 WTCD	Sample source:Kidney | Genotype:Wild-Type | Diet:Control	RAW_FILE_NAME(Raw Data File)=WT-CD 251
SUBJECT_SAMPLE_FACTORS           	-	120 WTCD	Sample source:Kidney | Genotype:Wild-Type | Diet:Control	RAW_FILE_NAME(Raw Data File)=WT-CD 120
SUBJECT_SAMPLE_FACTORS           	-	79 WTCD	Sample source:Kidney | Genotype:Wild-Type | Diet:Control	RAW_FILE_NAME(Raw Data File)=WT-CD 79
SUBJECT_SAMPLE_FACTORS           	-	129 WTCD	Sample source:Kidney | Genotype:Wild-Type | Diet:Control	RAW_FILE_NAME(Raw Data File)=WT-CD 129
SUBJECT_SAMPLE_FACTORS           	-	128 WTCD	Sample source:Kidney | Genotype:Wild-Type | Diet:Control	RAW_FILE_NAME(Raw Data File)=WT-CD 128
SUBJECT_SAMPLE_FACTORS           	-	92 WTCD	Sample source:Kidney | Genotype:Wild-Type | Diet:Control	RAW_FILE_NAME(Raw Data File)=WT-CD 92
SUBJECT_SAMPLE_FACTORS           	-	81 HZHFD	Sample source:Kidney | Genotype:Heterozygous | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=81 HZ-HFD
SUBJECT_SAMPLE_FACTORS           	-	95 HZHFD	Sample source:Kidney | Genotype:Heterozygous | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=95 HZ-HFD
SUBJECT_SAMPLE_FACTORS           	-	96 HZHFD	Sample source:Kidney | Genotype:Heterozygous | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=96 HZ-HFD
SUBJECT_SAMPLE_FACTORS           	-	123 HZHFD	Sample source:Kidney | Genotype:Heterozygous | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=123 HZ-HFD
SUBJECT_SAMPLE_FACTORS           	-	131 HZHFD	Sample source:Kidney | Genotype:Heterozygous | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=131 HZ-HFD
SUBJECT_SAMPLE_FACTORS           	-	136 HZHFD	Sample source:Kidney | Genotype:Heterozygous | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=136 HZ-HFD
SUBJECT_SAMPLE_FACTORS           	-	139 HZHFD	Sample source:Kidney | Genotype:Heterozygous | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=139 HZ-HFD
SUBJECT_SAMPLE_FACTORS           	-	29 WTHFD	Sample source:Kidney | Genotype:Wild-Type | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=29 WT-HFD
SUBJECT_SAMPLE_FACTORS           	-	83 WTHFD	Sample source:Kidney | Genotype:Wild-Type | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=83 WT-HFD
SUBJECT_SAMPLE_FACTORS           	-	91 WTHFD	Sample source:Kidney | Genotype:Wild-Type | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=91 WT-HFD
SUBJECT_SAMPLE_FACTORS           	-	124 WTHFD	Sample source:Kidney | Genotype:Wild-Type | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=124 WT-HFD
SUBJECT_SAMPLE_FACTORS           	-	133 WTHFD	Sample source:Kidney | Genotype:Wild-Type | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=133 WT-HFD
SUBJECT_SAMPLE_FACTORS           	-	134 WTHFD	Sample source:Kidney | Genotype:Wild-Type | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=134 WT-HFD
SUBJECT_SAMPLE_FACTORS           	-	138 WTHFD	Sample source:Kidney | Genotype:Wild-Type | Diet:Transfat	RAW_FILE_NAME(Raw Data File)=138 WT-HFD
SUBJECT_SAMPLE_FACTORS           	-	QC1	Sample source:Kidney | Genotype:QC | Diet:QC	RAW_FILE_NAME(Raw Data File)=QC1
SUBJECT_SAMPLE_FACTORS           	-	QC2	Sample source:Kidney | Genotype:QC | Diet:QC	RAW_FILE_NAME(Raw Data File)=QC2
SUBJECT_SAMPLE_FACTORS           	-	QC3	Sample source:Kidney | Genotype:QC | Diet:QC	RAW_FILE_NAME(Raw Data File)=QC3
SUBJECT_SAMPLE_FACTORS           	-	QC4	Sample source:Kidney | Genotype:QC | Diet:QC	RAW_FILE_NAME(Raw Data File)=QC4
SUBJECT_SAMPLE_FACTORS           	-	QC5	Sample source:Kidney | Genotype:QC | Diet:QC	RAW_FILE_NAME(Raw Data File)=QC5
#COLLECTION
CO:COLLECTION_SUMMARY            	Kidney samples were powdered with mortar and pestle. Initially, approximately 60
CO:COLLECTION_SUMMARY            	mg of each pulverized kidney sample was collected, then 50% Methanol: H2O (1 mg
CO:COLLECTION_SUMMARY            	tissue: 10 μL solvent) was added to each sample. After that, samples were
CO:COLLECTION_SUMMARY            	homogenized using a Qiagen TissueLyser LT system (Hilden, Germany). Next, 100
CO:COLLECTION_SUMMARY            	μL of each kidney homogenate was vigorously mixed (vortex 2 min) with 320 μL
CO:COLLECTION_SUMMARY            	of methanol. Subsequently, 80 μL of MTBE was added to each sample to extract
CO:COLLECTION_SUMMARY            	the lipid fraction from the kidneys. The samples were vigorously mixed for one
CO:COLLECTION_SUMMARY            	hour at room temperature, and then centrifuged (4000 g, 20 min, 20°C) to
CO:COLLECTION_SUMMARY            	facilitate phase separation.
CO:SAMPLE_TYPE                   	Kidney
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	The study focused on metabolic, histological, and metabolomic alterations
TR:TREATMENT_SUMMARY             	induced by a trans-fat-rich diet using wild-type C57Bl/6J mice, starting at 4
TR:TREATMENT_SUMMARY             	weeks old to 16 weeks. Mice were split into groups with a control diet, CD, (10%
TR:TREATMENT_SUMMARY             	fat, D12450B, Research Diets, USA) or a high trans-fat diet, TFD, (29% fat,
TR:TREATMENT_SUMMARY             	54.4% total kcal, TD.07011, ENVIGO, USA), containing 24% saturated, 61%
TR:TREATMENT_SUMMARY             	monounsaturated, and 15% polyunsaturated fats. To further evaluate the renal
TR:TREATMENT_SUMMARY             	effects of the TFD, Tgfβ3 heterozygous mice (Tgfβ3+/-) were also studied
TR:TREATMENT_SUMMARY             	alongside wild-type mice (Tgfβ3+/+), with both groups fed either a CD or TFD
TR:TREATMENT_SUMMARY             	from 4 to 16 weeks of age. Complete deletion of both Tgfβ3 alleles is lethal.
TR:TREATMENT_SUMMARY             	This animal model were grouped with the control or the trans-fat diets. After 16
TR:TREATMENT_SUMMARY             	weeks of age, Kidneys were collected and stored at -80°C. Kidney homogenate was
TR:TREATMENT_SUMMARY             	prepared by adding cold (−20 °C) methanol/water (1:1, v/v), (1:10
TR:TREATMENT_SUMMARY             	tissue/solvent). Tissue disruption was achieved with Tissue- Lyser LT
TR:TREATMENT_SUMMARY             	homogenizer (Qiagen, Germany) for metabolite extraction.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Depending on the specific metabolomic analysis, the samples were prepared as
SP:SAMPLEPREP_SUMMARY            	follows: LC-MS Analysis: 90 μL of the supernatant from each sample was
SP:SAMPLEPREP_SUMMARY            	transferred to chromatography vials. 45 μL was used for analysis in positive
SP:SAMPLEPREP_SUMMARY            	ionization mode (+), and another 45 μL was used for analysis in negative
SP:SAMPLEPREP_SUMMARY            	ionization mode. The supernatants were directly injected into the system for
SP:SAMPLEPREP_SUMMARY            	analysis. For GC−MS analysis, 300 μL of supernatant was evaporated to dryness
SP:SAMPLEPREP_SUMMARY            	(SpeedVac Concentrator System, Thermo Fisher Scientific, Waltham, MA).
SP:SAMPLEPREP_SUMMARY            	Methoxymation was then performed with 20 μL of O-methoxyamine hydrochloride (15
SP:SAMPLEPREP_SUMMARY            	mg/mL in pyridine) and vigorously vortex-mixed for 5 min. Vials were then
SP:SAMPLEPREP_SUMMARY            	incubated in darkness at room temperature for 16 h. For silylation, 20 μL of
SP:SAMPLEPREP_SUMMARY            	BSTFA/TMCS (99:1) was added and vortex-mixed for 5 min, and capped vials were
SP:SAMPLEPREP_SUMMARY            	placed in the oven at 70 °C for 1 h. Finally, 100 μL of heptane containing
SP:SAMPLEPREP_SUMMARY            	tricosane (10 ppm) as internal standard (IS) was added to each vial prior to
SP:SAMPLEPREP_SUMMARY            	injection. For LC−MS analysis, 90 μL of supernatant was transferred to an
SP:SAMPLEPREP_SUMMARY            	ultra-high-performance liquid chromatography−mass spectrometry.
SP:PROCESSING_STORAGE_CONDITIONS 	On ice
SP:EXTRACT_STORAGE               	-80℃
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	LC-MS (+) A UHPLC system (1290 Infinity UHPLC system, Agilent Technologies,
CH:CHROMATOGRAPHY_SUMMARY        	Waldbronn, Germany), consisting of two degassers, two binary pumps, and a
CH:CHROMATOGRAPHY_SUMMARY        	thermostated autosampler (maintained at 4°C) coupled with 6545 QTOF MS
CH:CHROMATOGRAPHY_SUMMARY        	detector, was used in positive and negative ESI modes. In brief, 1 μL of each
CH:CHROMATOGRAPHY_SUMMARY        	sample was injected into a reverse-phase Poroshell 120 Infinity Lab EC-C8 (2.1 x
CH:CHROMATOGRAPHY_SUMMARY        	150 mm, 2.7 µm) (Agilent Technologies) thermostated at 60°C. The gradient used
CH:CHROMATOGRAPHY_SUMMARY        	for the analysis consisted of a mobile phase A (10 mM ammonium formate in
CH:CHROMATOGRAPHY_SUMMARY        	Milli-Q water) and mobile phase B (10 mM ammonium formate in
CH:CHROMATOGRAPHY_SUMMARY        	methanol:isopropanol, 85:15) pumped at 0.5 mL/min. The chromatography gradient
CH:CHROMATOGRAPHY_SUMMARY        	started at 82% phase B, increasing to 90% B in 17 min. The gradient then
CH:CHROMATOGRAPHY_SUMMARY        	increased to 100% B by minute 18 and was maintained for 2 minutes until 20 min.
CH:CHROMATOGRAPHY_SUMMARY        	The starting condition was returned to by 21.5 min, followed by an 8.5 min
CH:CHROMATOGRAPHY_SUMMARY        	reequilibration time, taking the total run time to 30 min.
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Agilent 1290 Infinity II
CH:COLUMN_NAME                   	Agilent InfinityLab Poroshell 120 EC-C8 (150 x 2.1mm,2.7um)
CH:SOLVENT_A                     	100% water; 10 mM ammonium formate
CH:SOLVENT_B                     	85% methanol/15% isopropanol; 10 mM ammonium formate
CH:FLOW_GRADIENT                 	gradient started at 82% phase B, increasing to 90% B in 17 min. The gradient
CH:FLOW_GRADIENT                 	then increased to 100% B by minute 18 and was maintained for 2 minutes until 20
CH:FLOW_GRADIENT                 	min. The starting condition was returned to by 21.5 min, followed by an 8.5 min
CH:FLOW_GRADIENT                 	reequilibration time, taking the total run time to 30 min
CH:FLOW_RATE                     	0.5 mL/min
CH:COLUMN_TEMPERATURE            	60
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Agilent 6545 QTOF
MS:INSTRUMENT_TYPE               	QTOF
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	The mass spectrometry signals were processed following the procedure described
MS:MS_COMMENTS                   	by Armitage and colleagues (DOI:10.1128/AAC.02095-17). Data files generated from
MS:MS_COMMENTS                   	the instrumental analysis were processed using Agilent's Mass Hunter Profinder
MS:MS_COMMENTS                   	(B.08.00), a software employed for deconvolution, background noise removal, and
MS:MS_COMMENTS                   	integration of features obtained in the kidney samples of mice.The significant
MS:MS_COMMENTS                   	compounds obtained in the LC-MS analysis were annotated by combining information
MS:MS_COMMENTS                   	from spectral libraries (databases) and the data generated during LC-MS/MS
MS:MS_COMMENTS                   	(tandem mass spectrometry) experiments in both positive and negative ionization
MS:MS_COMMENTS                   	modes. The mass acquisition range was set in the interval of 50 to 3000 m/z for
MS:MS_COMMENTS                   	both ionizations. The identities were fragmented at 20 and 40 eV, and 1.5 µL of
MS:MS_COMMENTS                   	quality control samples were injected for each method developed in positive and
MS:MS_COMMENTS                   	negative ionization modes. Various spectral libraries were used for the
MS:MS_COMMENTS                   	annotation of unknown identities. Data were collected in full scan mode from 100
MS:MS_COMMENTS                   	to 1200 m/z, with a scan rate of 1.02 scans/s. The capillary voltage was set to
MS:MS_COMMENTS                   	3500 V; the drying gas flow rate was 12 L/min at 290°C and gas nebulizer 45
MS:MS_COMMENTS                   	psi, fragmentor voltage 175 V, and octopole radio frequency voltage (OCT RF Vpp)
MS:MS_COMMENTS                   	750 V. Two reference masses were used over the course of the whole analysis: m/z
MS:MS_COMMENTS                   	121.0509 (protonated purine) and m/z 922.0098 (protonated hexakis,
MS:MS_COMMENTS                   	(1H,1H,3H-tetrafluoropropoxy)phosphazine (HP-921)). These masses were
MS:MS_COMMENTS                   	continuously infused into the system to provide constant mass correction.
MS:MS_COMMENTS                   	Samples were randomly analyzed throughout the run.
MS:MS_RESULTS_FILE               	ST003738_AN006136_Results.txt	UNITS:arbitrary units, a.u.	Has m/z:Yes	Has RT:Yes	RT units:Minutes
#END